Navigation Links
Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
Date:1/23/2009

QUEBEC, Jan. 23 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX: VHB), announced today that its Neurobionix division has achieved ISO 13485:2003 certification for its Quality System Design Control. This certification, an internationally recognized management system standard developed by the International Organization for Standardization (ISO), complements the earlier certification that the Neurobionix division had received back in August 2008 for its manufacturing activities. The combination of both certifications guarantees that the design, development and manufacturing functions of the Company meet the highest quality standards known worldwide for implantable grade medical devices, including neuromodulation systems currently being developed for commercial release late 2009.

"This certification is an additional achievement resulting from the focus the Company has put in the repositioning of the Neurobionix division to become a product development engine capable of bringing innovative products to the market at quality standards expected by the implantable medical device industry and generally associated with larger companies", said Mr. Nader Kameli, Chief Operating Officer of the Neurobionix division.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix division focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix division develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.

Forward-Looking Statements

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.


'/>"/>
SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Victhom announces the completion of the second phase of the apnea therapy development
2. Victhom Announces Launch of Enhanced Company Website
3. Victhom to Participate in the OneMedPlace Finance Forum
4. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
5. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
6. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
7. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
9. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
10. HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services
11. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the ... research that could lead to one good one. Surviving Mesothelioma has just posted an ... The team evaluated 98 mesothelioma patients who got a second kind of ...
(Date:5/24/2016)... , May 24, 2016   MedyMatch Technology Ltd ... with artificial intelligence, real-time decision support tools in the emergency ... at the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... Israel,s 15th National Life Sciences and Technology ... the David Intercontinental Hotel in Tel Aviv, Israel ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2016. The cash dividend ... July 29, 2016 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:5/22/2016)... (PRWEB) , ... May 22, 2016 , ... Doctors in ... in combating the asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article ... in the University of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
Breaking Biology News(10 mins):